4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost protection against advanced non-small-cell lung cancer, with a so-called KRAS G12C mutation, which has progressed after previous treatment.

At the time of the decision, there were no results from direct comparative studies between Lumykras and the relevant comparator, docetaxel. An indirect comparison showed that patients treated with Lumykras live longer before disease progression compared to patients receiving docetaxel and that overall survival is longer with Lumykras.

Read TLV News [Swedish]